Limits...
HIV Drug Therapy in the Americas 16-18 April 2015, Mexico City, Mexico.

- J Int AIDS Soc (2015)

View Article: PubMed Central - PubMed

ABSTRACT

Antiretroviral therapies have proved life-saving in HIV infection, dramatically reducing morbidity and mortality. With longer survival, morbidities and mortalities in HIV infection are increasingly similar to the morbidities and mortalities associated with ageing. In treated HIV infection, the risk of these morbidities and mortalities is linked to immune activation, inflammation and coagulation indices. And in persons with treated HIV infection, failure to restore circulating CD4 T cell numbers is associated with a greater risk of morbidities and mortalities as well as to heightened levels of inflammation and coagulation. The drivers of immune activation, inflammation and coagulation in treated HIV infection are incompletely defined and could be related to sustained low levels of viral replication in tissues, to translocation of microbial products across a damaged gut mucosa, to replication of co-pathogens such as cytomegalovirus, to increased levels of inflammatory lipids, or to homeostatic responses to lymphocytopenia that may drive expansion of CD8 T cell numbers. We present here models that link inflammation and coagulation to morbid outcomes as well as to the pathogenesis of CD4 T cell restoration failure and CD8 T cell expansion.

No MeSH data available.


Data from the National System for Logistics Administration and Surveillance of ARV in Mexico (SALVAR) 31 of December, 2014. Database of the CIENI/CENSIDA, 2014. Database of the HIV Prison Programme in Mexico City 2014.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4401943&req=5

F0001_20135: Data from the National System for Logistics Administration and Surveillance of ARV in Mexico (SALVAR) 31 of December, 2014. Database of the CIENI/CENSIDA, 2014. Database of the HIV Prison Programme in Mexico City 2014.

Mentions: We started 2014 with 184 patients, adding 60 new patients throughout the year, 13 recidivists, 67 were freed and 9 died. At 31 December 2014, 206 HIV patients remained incarcerated, of which 92.2% (190) are linked and retained to health care (concentrated in the prison of Santa Martha Acatitla), of which 87.4% are on HAART, with 72.8% under virology control (VL<200) and 63.1% undetectable (VL<40) (Figure 1). Twenty-one percent (60) initiated HAART in the previous six months, 5.2% (10) initiated their HAART protocol, in virology failure 2.1% (4), 1% (2) with persistent low grade viraemia (VL<1000) and 2.1% (4) with blip. Of the 67 patients that were freed, 91% (61) continued their medical treatment at the Condesa Specialized Clinic.


HIV Drug Therapy in the Americas 16-18 April 2015, Mexico City, Mexico.

- J Int AIDS Soc (2015)

Data from the National System for Logistics Administration and Surveillance of ARV in Mexico (SALVAR) 31 of December, 2014. Database of the CIENI/CENSIDA, 2014. Database of the HIV Prison Programme in Mexico City 2014.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4401943&req=5

F0001_20135: Data from the National System for Logistics Administration and Surveillance of ARV in Mexico (SALVAR) 31 of December, 2014. Database of the CIENI/CENSIDA, 2014. Database of the HIV Prison Programme in Mexico City 2014.
Mentions: We started 2014 with 184 patients, adding 60 new patients throughout the year, 13 recidivists, 67 were freed and 9 died. At 31 December 2014, 206 HIV patients remained incarcerated, of which 92.2% (190) are linked and retained to health care (concentrated in the prison of Santa Martha Acatitla), of which 87.4% are on HAART, with 72.8% under virology control (VL<200) and 63.1% undetectable (VL<40) (Figure 1). Twenty-one percent (60) initiated HAART in the previous six months, 5.2% (10) initiated their HAART protocol, in virology failure 2.1% (4), 1% (2) with persistent low grade viraemia (VL<1000) and 2.1% (4) with blip. Of the 67 patients that were freed, 91% (61) continued their medical treatment at the Condesa Specialized Clinic.

View Article: PubMed Central - PubMed

ABSTRACT

Antiretroviral therapies have proved life-saving in HIV infection, dramatically reducing morbidity and mortality. With longer survival, morbidities and mortalities in HIV infection are increasingly similar to the morbidities and mortalities associated with ageing. In treated HIV infection, the risk of these morbidities and mortalities is linked to immune activation, inflammation and coagulation indices. And in persons with treated HIV infection, failure to restore circulating CD4 T cell numbers is associated with a greater risk of morbidities and mortalities as well as to heightened levels of inflammation and coagulation. The drivers of immune activation, inflammation and coagulation in treated HIV infection are incompletely defined and could be related to sustained low levels of viral replication in tissues, to translocation of microbial products across a damaged gut mucosa, to replication of co-pathogens such as cytomegalovirus, to increased levels of inflammatory lipids, or to homeostatic responses to lymphocytopenia that may drive expansion of CD8 T cell numbers. We present here models that link inflammation and coagulation to morbid outcomes as well as to the pathogenesis of CD4 T cell restoration failure and CD8 T cell expansion.

No MeSH data available.